10-QPeriod: Q3 FY2005

QUEST DIAGNOSTICS INC Quarterly Report for Q3 Ended Sep 30, 2005

Filed October 28, 2005For Securities:DGX

Summary

Quest Diagnostics Inc. (DGX) reported for the third quarter of 2005 solid revenue growth of 6.4%, reaching $1.37 billion, and a 5.9% increase for the nine-month period to $4.07 billion. This growth was driven by higher testing volumes and an increase in average revenue per requisition, indicating a favorable shift in test mix towards higher-value services like gene-based and esoteric testing. Despite facing headwinds such as the impact of hurricanes in the Gulf Coast and operational issues at its test kit manufacturing subsidiary (NID), the company demonstrated resilience. Net income for the quarter rose to $135.2 million ($0.66 per diluted share) from $130.1 million ($0.62 per diluted share) in the prior year, and year-to-date net income increased to $415.9 million ($2.02 per diluted share) from $373.1 million ($1.75 per diluted share). The company also announced a significant pending acquisition of LabOne, Inc. for approximately $980 million, which is expected to close in early November 2005, signaling a strategic move to expand its service offerings.

Key Highlights

  • 1Net revenues increased by 6.4% to $1.37 billion for the three months ended September 30, 2005, compared to the prior year period.
  • 2Net income for the third quarter of 2005 was $135.2 million, or $0.66 per diluted share, up from $130.1 million, or $0.62 per diluted share, in the prior year.
  • 3The company is undertaking a significant acquisition of LabOne, Inc. for an estimated $980 million, expected to close in early November 2005.
  • 4Clinical testing volume increased by 4.0% year-over-year for the nine-month period, and average revenue per requisition improved, reflecting a favorable shift in test mix.
  • 5The company's test kit manufacturing subsidiary (NID) faced operational challenges, including a voluntary product hold and government subpoenas, impacting revenues and costs.
  • 6Quest Diagnostics successfully redeemed its contingent convertible debentures in January 2005, leading to a reduction in interest expense.
  • 7The company repurchased approximately $190 million of its common stock in the first nine months of 2005, continuing its share repurchase program.

Frequently Asked Questions

For the third quarter of 2005, Quest Diagnostics reported net revenues of $1.37 billion, a 6.4% increase compared to the prior year. Net income was $135.2 million, or $0.66 per diluted share, up from $130.1 million, or $0.62 per diluted share, in the same period of 2004. This growth was driven by higher testing volumes and improved average revenue per requisition.

Key drivers of financial performance include growth in clinical laboratory testing volumes and a shift towards higher-value tests. However, the company also faced challenges, including the impact of hurricanes in the Gulf Coast region and operational issues at its test kit manufacturing subsidiary (NID), which affected revenues and increased costs.

Quest Diagnostics signed a definitive agreement to acquire LabOne, Inc. for approximately $980 million in an all-cash transaction. The acquisition, which is expected to close in early November 2005, is subject to customary conditions and has received approval from LabOne shareholders and antitrust clearance.

The company successfully redeemed its contingent convertible debentures in January 2005, reducing interest expenses. They also continued their share repurchase program, buying back approximately $190 million of common stock in the first nine months of 2005. The company's dividend per common share increased to $0.09 in Q3 2005 from $0.075 in Q3 2004.